Edit
Biosplice Therapeutics
https://www.biosplice.com/default.aspxLast activity: 08.03.2024
Probably Closed
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.
Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center.
Biosplice's leading drug is targeted to treat knee osteoarthritis with the goal of alleviating pain and the aim of restoring tissue balance and protecting from cartilage loss. Biosplice's clinical pipeline also focuses on oncology, with additional early-stage programs in neurology and other areas of significant unmet medical needs.
Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center.
Biosplice's leading drug is targeted to treat knee osteoarthritis with the goal of alleviating pain and the aim of restoring tissue balance and protecting from cartilage loss. Biosplice's clinical pipeline also focuses on oncology, with additional early-stage programs in neurology and other areas of significant unmet medical needs.
Location: United States, California, San Diego
Total raised: $120M
Investors 2
| Date | Name | Website |
| 20.01.2022 | aMoon Fund | amoon.fund... |
| - | SymBiosis | symbiosis.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.04.2021 | - | $120M | aMoon Fund |
Mentions in press and media 3
| Date | Title | Description |
| 08.03.2024 | Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program | The competitive Department of Defense “Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Translational Research Award” will fund preclinical development of Biosplice’s DYRK inhibitors in traumatic brain injury (TBI)... |
| 08.03.2024 | Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program | - |
| 08.03.2023 | Finding the Fountain of Youth: Meet the Startups Pioneering Longevity Solutions | If technology allowed humanity to live forever in the future, would you take the ticket? We asked our readers recently and were surprised to see the balance tilt towards “No” (60% of respondents). One answer was hidden in a comment from one... |